NeurologyLive® Friday 5 — February 3, 2023

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: 5 Clinical Trial Readouts in Neurology to Look for in 2023

Over the years, drug development has continued to boom throughout neurology, with record-setting amounts of funding and first-time disease-modifying therapies being introduced. There are several hundreds of ongoing trials assessing potential agents for patients with neurological conditions, all across different phases. Take a look at 5 clinical trials with expected data readouts in 2023 that NeurologyLive® will have its eye on.

2: Peer Exchange: Management of Amyloid Related Imaging Abnormalities (ARIA) for Alzheimer’s Disease

In episode 14 of this Peer Exchange, the panel of experts in dementia commented on the observation of amyloid related imaging abnormalities (ARIA) seen with many Alzheimer’s disease treatments and shared their thoughts on management of ARIA. The NeurologyLive^® series panel features Marwan Sabbagh, MD; Alireza Atri, MD, PhD; Sharon Cohen, MD, FRCPC; and Eric McDade, DO.

3: NeuroVoices: Rachel Alvarez on Identifying Key Treatment Needs for Congenital Muscular Dystrophies

In the latest edition of our in-depth Q&A series, the executive direct of Cure CMD discussed the treatment landscape for CMDs, and where improvements can be made. She spoke on the need for improved awareness, early detection, and role neurologists play early in a patient’s life. Additionally, she spoke on the state of gene therapies, the challenges that remain, and why these approaches don’t do much for adults with CMDs.

4: Case Study and Overview of WAKIX® (pitolisant) Tablets in the Treatment of Excessive Daytime Sleepiness and/or Cataplexy in Adults with Narcolepsy

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center and professor of neurology at Albert Einstein College of Medicine reviewed the safety and efficacy data for WAKIX® (pitolisant) from clinical studies, as well as a clinical case study of a patient with type 1 narcolepsy who started treatment with WAKIX. It is the first and only FDA-approved non-scheduled therapeutic option for this patient group.

5: Educating and Easing Interdisciplinary Care Teams to Treat Parkinson Disease: Eli Pollard

The chief training and education officer at the Parkinson’s Foundation provided perspective on the range of community providers who can benefit from this series. Additionally, she spoke about the most troubling symptoms patients face and why a group of well-rounded clinicians are needed to tackle such issues. [WATCH TIME: 4 minutes]